Nasdaq:US$15.97 (+1.13) | HKEX:HK$25.36 (+0.34) | AIM:£2.31 (-0.02)
搜索
News & Press Releases
123456789101112
13
141516171819
找到相关结果： 945
演示文稿, 科学出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
阅读更多
公告及新闻稿, 监管通知 | 2017-03-31

Total Voting Rights
London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary sh
阅读更多
公告及新闻稿, 监管通知 | 2017-03-29

Vesting of awards under the Long Term Incentive Plan
公告及新闻稿, 监管通知 | 2017-03-28

Grant of Share Options under Share Option Scheme
London: Tuesday, March 28, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 27, 2017, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
阅读更多
公告及新闻稿, 集团 | 2017-03-27

2016 Annual Report and Notice of Annual General Meeting
London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-03-24

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors
Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017
Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o
阅读更多
公告及新闻稿, 监管通知 | 2017-03-20

Directors’ Share Dealing
London: Monday, March 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-03-16

Grant of Awards under Long Term Incentive Plan
Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a
阅读更多
公告及新闻稿, 集团 | 2017-03-13

Publication of Form 20-F for the Year Ended December 31, 2016
London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww
阅读更多
公告及新闻稿, 集团 | 2017-03-13

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-10

和黄医药在欧洲神经内分泌肿瘤学会年会上公布索凡替尼治疗神经内分泌瘤Ib/II期临床试验结果
2017年3月10日：和黄医药在2017年3月8日至10日于西班牙巴塞罗那举行的第14届欧洲神经内分泌肿瘤学会年会（ENETS）上公布了索凡替尼正在进行的治疗晚期神经内分泌瘤的Ib/II期临床试验结果。
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2017-03-09

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2017-03-03

和黄医药宣布呋喹替尼（HMPL-013）以局部晚期或转移性结直肠癌为适应症的III期临床试验“FRESCO”取得成功
  –达到首要和次要终点 – – 安全性及疗效达到预期 – –计划于2017年中递交中国新药上市申请– –完整详细的试验结果将在2017年中通过肿瘤学术大会公布–   2017年3月3日：
阅读更多
查看公告 (PDF)
公告及新闻稿, 新闻稿, 集团 | 2017-02-28

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee
Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-20

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia
London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia.  HMPL-453 is a novel, highly
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
Press Release London: Tuesday, February 14, 2017:  Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi
阅读更多
公告及新闻稿, 监管通知 | 2017-02-06

Chi-Med to Announce 2016 Final Results
London: Monday, February 6, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). An analy
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-02-01

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors
Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director
阅读更多
演示文稿, 科学出版物 | 2017-01-20

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer
A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,
阅读更多
演示文稿, 科学出版物 | 2017-01-19

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study   Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2017-01-16

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors
Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China.  Sulfatinib
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium
London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-10

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo
阅读更多
公告及新闻稿, 监管通知 | 2016-12-30

Total Voting Rights
London: Friday, December 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 30, 2016, the issued share capital of Chi-Med consisted of 60,705,823 ordin
阅读更多
公告及新闻稿, 监管通知 | 2016-12-29

Blocklisting Six Monthly Return
London: Thursday, December 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchis
阅读更多
公告及新闻稿, 监管通知 | 2016-12-20

Director’s Share Dealing
London: Tuesday, December 20, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: CM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 17,839 American Depositary Shares of the Company (
阅读更多
公告及新闻稿, 监管通知 | 2016-12-14

Director’s Share Dealing
London: Wednesday, December 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Simon To, executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Compan
阅读更多
演示文稿, 科学出版物 | 2016-12-06

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC
A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer  (NCT02590965) Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-12-06

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl
阅读更多
演示文稿, 科学出版物 | 2016-12-06

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo
HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We
阅读更多
演示文稿, 科学出版物 | 2016-12-05

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis
A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,
阅读更多
公告及新闻稿, 监管通知 | 2016-11-30

Exercise of Share Options by a Person Discharging Managerial Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Respons
阅读更多
公告及新闻稿, 监管通知 | 2016-11-30

Total Voting Rights
London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 or
阅读更多
公告及新闻稿, 监管通知 | 2016-11-23

Director’s Share Dealing
London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-23

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)
Press Release London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer (“NSCLC”) clinical studies will be presented at WCLC in Vienn
阅读更多
演示文稿, 科学出版物 | 2016-11-14

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian Male Healthy Subjects   Background: S
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-11-14

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti
阅读更多
公告及新闻稿, 监管通知 | 2016-11-01

Director's Share Dealing
London: Tuesday, November 1, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the
阅读更多
公告及新闻稿, 其他业务, 新闻稿 | 2016-10-31

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment
Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen
阅读更多
公告及新闻稿, 监管通知 | 2016-10-12

Director's Share Dealing
London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (
阅读更多
公告及新闻稿, 监管通知 | 2016-08-09

Director's Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Change of Non-executive Directors
London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha
阅读更多
公告及新闻稿, 集团 | 2016-08-02

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment.   Innovation Platform – Seven drug candidates in 25
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2016-08-01

为加快沃利替尼全球研发项目，和黄医药与阿斯利康签署共同开发补充协议
首个以c-Met异常乳头状肾细胞癌（“PRCC”）为适应症的全球III期临床试验将于近期启动   2016年8月1日：和黄医药和阿斯利康今日宣布在2011年双方就沃利替尼达成的合作协议的基础上签
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2016-07-05

Chi-Med to Announce 2016 Half-Year Financial Results
London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a
阅读更多
公告及新闻稿, 监管通知 | 2016-06-29

Blocklisting Six Monthly Return
123456789101112
13
141516171819